STOCK TITAN

AMGEN Inc. - AMGN STOCK NEWS

Welcome to our dedicated news page for AMGEN (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on AMGEN.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AMGEN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AMGEN's position in the market.

Rhea-AI Summary
Amgen announces positive results from the Phase 2a COURSE trial for TEZSPIRE® in COPD, showing a reduction in annualized rate of moderate or severe exacerbations by 17%. Planning for Phase 3 development of tezepelumab is underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences clinical trial
-
Rhea-AI Summary
Amgen announces positive 52-week data for Otezla in children with plaque psoriasis and successful late-breaking Phase 3 study results for palmoplantar pustulosis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Amgen (AMGN) declares $2.25 per share dividend for Q2 2024, payable on June 7, 2024, to stockholders of record as of May 17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
dividends
Rhea-AI Summary
Amgen (NASDAQ:AMGN) executives to present at the 44th Annual TD Cowen Health Care Conference. Webcast available for investors and the public. Amgen launches 'Amgen Perspectives in Obesity' website for additional information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
conferences
-
Rhea-AI Summary
Amgen (AMGN) unveils its cutting-edge manufacturing facility, Amgen Ohio, in Central Ohio. The facility, spanning 300,000 square feet, will employ 400 staff, focusing on innovative biomedicines. Amgen aims for carbon neutrality by 2027, emphasizing sustainability. The site also supports the local community through job creation and a manufacturing apprenticeship program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
Rhea-AI Summary
Amgen (AMGN) will host a webcast to discuss Rare Disease as its new growth pillar, highlighting strategies, products, and pipeline opportunities. Key executives will participate in the conference call, emphasizing the company's focus on rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
conferences
Rhea-AI Summary
Amgen (AMGN) executives to present at Oppenheimer Healthcare Life Sciences Conference. Webcast available for replay on Amgen's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Amgen (AMGN) reported a 20% increase in total revenues for the fourth quarter of 2023, driven by a 23% volume growth in product sales. However, GAAP earnings per share decreased by 53% due to acquisition-related expenses and incremental operating expenses from Horizon. Non-GAAP EPS increased by 15% for the quarter. The company generated $7.4 billion of free cash flow for the full year, primarily driven by transaction expenses related to the Horizon acquisition and higher repatriation tax payments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.39%
Tags
-
Rhea-AI Summary
Amgen (NASDAQ:AMGN) is set to report its fourth quarter and full year 2023 financial results on February 6, 2024, followed by a conference call with the investment community. The live audio of the call will be broadcast over the internet and archived for replay for at least 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
Rhea-AI Summary
A study published in Nature Structural & Molecular Biology by deCODE genetics, a subsidiary of Amgen, revealed that a low-frequency missense variant in the SYCE2 gene increases the risk of pregnancy loss by 22%. The study involved over 114 thousand women from multiple countries and demonstrated that the variant affects recombination, potentially contributing to pregnancy loss. The findings highlight the impact of genetic variants on pregnancy outcomes and provide valuable insights into the biology behind pregnancy losses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
AMGEN Inc.

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

142.36B
534.35M
0.25%
80.73%
1.95%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Thousand Oaks

About AMGN

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.